Research Article A Computational Approach to Justifying Stratifin as a Candidate Diagnostic and Prognostic Biomarker for Pancreatic Cancer Md Roman Mogal , 1 Asadullah Junayed, 1 Md Rashel Mahmod, 1 Sagarika Adhikary Sompa, 1 Suzana Afrin Lima, 1 Newton Kar, 1 TasminaTarin, 1 Marina Khatun, 1 Md Abu Zubair, 2 and Md Asaduzzaman Sikder 1 1 Department of Biochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail 1902, Bangladesh 2 Department of Food Technology and Nutritional Science, Mawlana Bhashani Science and Technology University, Tangail 1902, Bangladesh Correspondence should be addressed to Md Asaduzzaman Sikder; sikderma@mbstu.ac.bd Received 17 November 2021; Revised 28 March 2022; Accepted 12 April 2022; Published 2 May 2022 Academic Editor: Gerard M. Moloney Copyright © 2022 Md Roman Mogal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Pancreatic cancer (PC) is considered a silent killer because it does not show specific symptoms at an early stage. Thus, identifying suitable biomarkers is important to avoid the burden of PC. Stratifin (SFN) encodes the 14-3-3σ protein, which is expressed in a tissue-dependent manner and plays a vital role in cell cycle regulation. Thus, SFN could be a promising therapeutic target for several types of cancer. This study was aimed at investigating, using online bioinformatics tools, whether SFN could be used as a diagnostic and prognostic biomarker in PC. SFN expression was explored by utilizing the ONCOMINE, UALCAN, GEPIA2, and GENT2 tools, which revealed that SFN expression is higher in PC than in normal tissues. The clinicopathological analysis using the ULCAN tool showed that the intensity of SFN expression is commensurate with cancer progression. GEPIA2, R2, and OncoLnc revealed a negative correlation between SFN expression and survival probability in PC patients. The ONCOMINE, UCSC Xena, and GEPIA2 tools showed that cofilin 1 is strongly coexpressed with SFN. Moreover, enrichment and network analyses of SFN were performed using the Enrichr and NetworkAnalyst platforms, respectively. Receiver operating characteristic (ROC) curves revealed that tissue-dependent expression of the SFN gene could serve as a diagnostic and prognostic biomarker. However, further wet laboratory studies are necessary to determine the relevance of SFN expression as a biomarker. 1. Introduction The pancreas is a pear-shaped organ located in the abdo- men, and it plays an essential role in converting foods to become fuel for body cells. However, in some cases, the growth of the pancreas becomes uncontrollable due to some reasons and thus becomes cancerous. Pancreatic can- cer (PC) is one of the deadliest cancers and is the seventh most common cause of cancer-related deaths in both men and women [1]. According to GLOBOCAN, in 2018, the estimated number of PC cases and deaths were 458,918 and 432,242, respectively, corresponding to 2.5% of all new cancer diagnoses and 4.5% of all cancer deaths [1]. PC has become more common in recent decades, and the number of new cases will reach 355,317 by 2040 [2, 3]. PC incidence is 3–4 times greater in developed coun- tries than in developing and poor countries [4]. In the United States, it is estimated that in 2021, approximately 60,430 individuals (31,950 men and 28,480 women) will be diagnosed with PC and approximately 48,220 individ- uals (25,270 men and 22,950 women) will die of PC [5]. Furthermore, PC is expected to overtake breast cancer as the third leading cause of cancer-related death in the European Union, as in the United States [3, 6]. Hindawi BioMed Research International Volume 2022, Article ID 1617989, 17 pages https://doi.org/10.1155/2022/1617989